logo
  

Halcon Resources Slips To Loss In Q2; Adj. Profit Up; Revises FY Production View

Halcon Resources Corp. (HK) reported net loss available to common stockholders for the second quarter of $73.33 million or $0.18 per share, compared to net income of $36.37 million or $0.08 per share for the year-ago quarter.

After adjusting for selected items primarily related to the non-cash impact of derivatives, adjusted net income was $32.5 million, or $0.07 per diluted share versus $16.8 million or $0.04 per share in the prior year.

Total operating revenues for the quarter rose 53 percent to $327.1 million from $214.34 million in the prior-year period.

Analysts polled by Thomson Reuters expected the company to earn $0.04 per share for the quarter on revenue of $303.63 million.

The company noted that production for the quarter came in above guidance and increased 44% year-over-year to an average of 42,055 barrels of oil equivalent per day.

The company has previously said it entered into a purchase and sale agreement to divest non-core assets in East Texas for $450 million. The deal is expected to close in May 2014 with an effective date of April 1, 2014. The Company continues to evaluate all remaining non-core properties for additional divestiture opportunities during 2014.

Looking ahead, Halcon Resources forecast production for the third quarter in a range of 41,000 Boe/d to 43,000 Boe/d and revises its full-year 2014 production guidance of 40,000 Boe/d to 42,000 Boe/d from prior view of of 38000 Boe/d to 42000 Boe/d.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT